FOXO4-DRI

FOXO4-DRI at a Glance

FOXO4-DRI is a designed senolytic — a peptide built to kill senescent cells rather than to signal to healthy ones. Senescent cells stop dividing but resist dying, accumulating with age and secreting inflammatory factors; FOXO4-DRI works by disrupting the FOXO4–p53 interaction those cells depend on to stay alive, releasing p53 to trigger apoptosis. The “DRI” refers to its retro-inverso design, built from D-amino acids in reverse order to resist degradation. It is preclinical, with no human data.

History & Development

FOXO4-DRI is designed to kill cells - specifically senescent ones. That makes it categorically different from everything else on this hub, which signals rather than destroys.

First described	Not established in the sources consulted for this section
Discovered / synthesised by	Not established in the sources consulted for this section
Institution	Not established in the sources consulted for this section
Origin	Synthetic 46-residue construct (MW ~5,358) - a D-retro-inverso isoform of a FOXO4 fragment fused to a cationic cell-penetrating sequence
Key patent	Not established in the sources consulted for this section
Assignee	Not established in the sources consulted for this section
Development status	Preclinical only; never approved anywhere

Discovery

Senescent cells stop dividing but refuse to die, accumulating with age and secreting inflammatory signals. Senolytics aim to remove them, and FOXO4-DRI is a designed one.

Its target is a protein-protein interaction. In senescent cells, FOXO4 sequesters p53, preventing it from triggering apoptosis - which is part of how those cells survive. FOXO4-DRI is built to disrupt that interaction, releasing p53 so the senescent cell dies as it otherwise would.

The construction is unusually elaborate for a peptide sold retail. A D-retro-inverso isoform uses D-amino acids in reversed sequence, presenting a similar side-chain topology while resisting proteases; that is fused to a cationic cell-penetrating sequence to get the construct inside cells. It is a designed intracellular disruptor, not a receptor ligand.

Development & ownership

The evidence is entirely preclinical, and the mechanism carries a risk profile unlike anything else here. A compound that triggers apoptosis by freeing p53 is not selective by virtue of intent - selectivity depends on senescent cells’ particular dependence on FOXO4 sequestration, and any off-target apoptosis is cell death rather than a side effect in the ordinary sense.

There is no human trial, no established dose, and no human safety data.

How it reached the market

FOXO4-DRI is sold as an injectable senolytic for anti-ageing. What is being bought is a preclinical cell-penetrating construct designed to induce programmed cell death, with no human data of any kind - which is a materially different proposition from a peptide that nudges a receptor.

What It's Used For

FOXO4-DRI is a synthetic senolytic peptide — a 46-residue construct (MW ≈ 5,358) built as a D-retro-inverso isoform of a FOXO4 fragment fused to a cationic cell-penetrating import sequence. It was engineered in 2017 as a proof-of-concept tool compound to test a specific idea: that senescent (“zombie”) cells stay alive because the transcription factor FOXO4 sequesters p53, and that breaking that interaction would release p53 and let the cell kill itself. The single fact that should frame everything else here is that FOXO4-DRI’s reputation rests almost entirely on one paper — Baar et al., Cell 2017, from Peter de Keizer’s group — which reported that the peptide selectively killed senescent cells and, in both progeroid and naturally aged mice, restored running fitness, fur density and renal function ^{1Reference 1Baar MP et al. · 2017In vitroTargeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging — animal (mouse) / in vitroView study →}.

That result is genuinely striking and the paper is real and heavily cited. But nine years later, no independent group has reproduced the aging-reversal phenotype. Other labs have picked the peptide up and used it as a tool in disease models — bleomycin lung fibrosis, senescent Leydig cells, keloid fibroblasts, cultured chondrocytes — and it does appear to do something senolytic in independent hands. Nobody has re-run the headline experiment. Meanwhile the one large independent study to test senescent-cell clearance in a different organ found the opposite of benefit: eliminating senescent cells, FOXO4-DRI included, promoted pulmonary hypertension ^{16Reference 16Born E et al. · 2023AnimalEliminating senescent cells can promote pulmonary hypertension development and progression — animal (mouse) / human tissueView study →}.

There is no human data of any kind — no trial, no pharmacokinetics, no toxicology — and zero registered studies on ClinicalTrials.gov. Route is load-bearing: a ~5.4 kDa peptide has no meaningful oral absorption, so every published result comes from injection, mostly intravenous in mice. It is an unapproved research chemical sold gray-market, and the “reverses aging in humans” framing built around it is an extrapolation from one mouse study that no human study has ever tested.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. For FOXO4-DRI the ceiling is deliberately low — nothing here clears 32%, because every row is animal or cell data and there is no human study of any kind. Two rows are not scored at all, and for opposite reasons: brain aging because I could not locate a single primary study behind the claim, and pulmonary hypertension because the evidence there points the wrong way — it is a harm finding, not a low score for lack of testing. Each application links down to its write-up.

01Chemotoxicity protection & aging healthspanShaky30%The founding mouse + in-vitro study; broad endpoints but a single originating lab, never independently replicated; no human data

02Pulmonary fibrosisShaky28%Two independent bleomycin mouse studies (one carries a 2024 published Correction); animal-only

03Senescent cancer-cell clearanceShaky26%Mouse NSCLC radiosensitization + in-vitro/computational peptide-design work; no clinical oncology data

04Age-related hypogonadism & spermatogenesisShaky24%Two aged-mouse + TM3-cell studies, closely related authorship; no human fertility data

05Keloid scar fibroblastsShaky20%Single 2025 cell/tissue study

06Cartilage & post-traumatic osteoarthritisShaky18%Single in-vitro study on expanded human chondrocytes; no joint or clinical data

07Vascular & endothelial agingShaky16%Single 2025 cell study

08Brain aging & cognitive declineShaky0%Claim traced to one 2026 narrative review; no primary FOXO4-DRI brain or cognition study located

09Pulmonary hypertension: evidence of harmShaky0%Independent 2023 Circulation study — senescent-cell clearance worsened disease. Not a benefit; listed so it is not missed

Mechanisms

Pharmacokinetics

There is no human pharmacokinetic data for FOXO4-DRI. None. No half-life, no clearance, no volume of distribution, no tissue distribution, no CNS penetration, no bioavailability figure — because the compound has never been administered in a registered human study.

What is known is structural. FOXO4-DRI is a 46-residue synthetic peptide (MW ≈ 5,358) built in the D-retro-inverso configuration: it is assembled from D-amino acids in reversed sequence, so that the side-chain topology approximates the natural L-peptide while the backbone is unrecognizable to proteases. This is legitimate, well-established medicinal chemistry with a clear rationale — a native L-peptide of this kind would be degraded too quickly to do anything — and it is also why the molecule is expensive and technically demanding to make correctly. But it is worth being precise about what the design buys: DRI is a stability solution, not an efficacy claim. It makes the peptide last; it does not make it work, and it does not make it selective.

It also introduces its own open questions. D-amino-acid peptides are poorly cleared by the normal proteolytic machinery, and can show very long tissue residence compared with their L-counterparts. For a compound whose purpose is to trigger apoptosis, that cuts both ways: it may allow effective dosing at low frequency, and it may mean that if something goes wrong there is no quick way to stop it. Neither the benefit nor the risk has been quantified in a human.

The C-terminal arginine/lysine-rich segment is a cell-penetrating “import” sequence that carries the FOXO4-derived portion into cells; notably, the 2025 NMR study found this cationic segment is not merely a delivery tag but contributes to p53 binding itself ^{14Reference 14Bourgeois B et al. · 2025In vitroThe disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — in vitro (structural NMR; co-authored by the originating investigator, part-funded by Cleara Biotech)View study →}. The compound is supplied as a lyophilized powder for reconstitution. Like essentially all peptides of this size, oral bioavailability is negligible, so all published dosing is parenteral — intravenous (occasionally intraperitoneal) in mice, with the founding regimen being 3 × 5 mg/kg i.v. on alternating days ^{1Reference 1Baar MP et al. · 2017In vitroTargeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging — animal (mouse) / in vitroView study →}. There is no oral, intranasal or transdermal form with any supporting data.

Clinical & regulatory status

FOXO4-DRI is an unapproved research chemical. It has never been approved by the FDA, EMA, TGA, PMDA or any comparable regulator for any indication in any country; it is neither a medicine nor a dietary supplement, and there is no approval document or drug label to cite — only the absence of one. It is not currently a scheduled or controlled substance. It is sold as a research reagent labeled “not for human consumption.”

There are zero registered clinical trials of FOXO4-DRI. A ClinicalTrials.gov v2 API query by intervention returns 0 studies for FOXO4-DRI and 0 for FOXO4 generally (checked July 2026). For calibration, the same registry holds 31 studies tagged senolytic, including completed human trials of dasatinib + quercetin and of fisetin — so the senolytic field as a whole has reached humans; this compound has not. That comparison is the fairest way to read FOXO4-DRI’s status: not “a senolytic, and senolytics are being trialled,” but “the one senolytic in this class that nobody has taken into a person.”

Nor is it obviously on its way there. The originating investigator co-founded Cleara Biotech (Utrecht) to commercialize this mechanism, and the company’s own materials describe its lead development candidates as CL04177 and CL04183 — optimized molecules with enhanced binding to phosphorylated p53 — evaluated in cell, organoid and mouse models and described as heading toward clinical trials. FOXO4-DRI itself is not presented as the clinical candidate. Read plainly: the people who invented it are developing something else. (Company statements are attributed inline here because they are not peer-reviewed sources and carry no PMID.) The same pattern shows in the wider literature: other groups pursuing the FOXO4 target have moved to different modalities entirely, such as FOXO4-targeting DNA nanoparticles for senescent lung fibroblasts ^{17Reference 17Han Y et al. · 2023In vitroDNA nanoparticles targeting FOXO4 selectively eliminate cigarette smoke-induced senescent lung fibroblasts — in vitro (alternative delivery, not the DRI peptide)View study →} — adjacent technology aimed at the same protein, not this peptide.

Last checked: July 2026.

Sourcing, Route & Legal Status

Regulatory status — never approved anywhere. FOXO4-DRI holds no marketing authorization in any jurisdiction and never has. It is not a drug, not a dietary supplement, and not an ingredient with any recognized food or supplement status. It is not scheduled or controlled, but its sale for human use is unlawful in most jurisdictions precisely because it is an unapproved new drug being marketed for effect. Any human use is uncontrolled self-experimentation with a compound that has never entered a human trial.

How it’s supplied & administered. It is supplied as a lyophilized (freeze-dried) powder requiring reconstitution in bacteriostatic water or buffer. Because a ~5.4 kDa peptide is not meaningfully absorbed orally, all documented administration is by injection — intravenous and intraperitoneal in the animal work; the self-experimenting community uses subcutaneous injection, which has no supporting data at all. There is no oral, nasal or transdermal product with any evidence behind it. The D-retro-inverso design improves chemical stability, but reconstituted material still requires cold storage and has finite working stability.

The stereochemistry problem — this is the compound-specific sourcing argument, and it is a serious one. Most gray-market peptide risk is generic: wrong content, degradation, endotoxin. FOXO4-DRI has an additional and unusually severe problem. It is a 46-residue all-D-amino-acid peptide synthesized in reverse. That is a genuinely difficult and expensive synthesis: D-amino-acid building blocks cost substantially more than L, and a 46-mer requires 46 sequential couplings, every one of which must use the correct enantiomer. A batch made with cheaper L-residues, or with partial racemization, or assembled in the wrong direction, would be a different molecule — one that is proteolytically fragile and would be destroyed before it did anything.

And here is the part that matters most: no standard purity certificate demonstrates stereochemistry. HPLC purity tells you the material is one dominant species. Mass spectrometry tells you the mass is right — and D- and L-amino acids have identical mass. A vial containing the all-L peptide, or a partially racemized mixture, can return a perfectly clean COA showing “>98% purity, mass confirmed.” Establishing that a peptide is genuinely all-D in reverse sequence requires chiral analysis (chiral GC/LC of the hydrolysate) or comparative degradation testing, which essentially no vendor performs and no buyer requests. The realistic conclusion is that the probability gray-market “FOXO4-DRI” is actually the specified stereochemistry is low, unverifiable, and not addressed by any document a vendor is likely to provide.

The rest of the sourcing reality. Beyond stereochemistry, the usual unregulated-supply problems all apply: no manufacturing oversight, no pharmacopoeial standard, no regulatory accountability, unverified peptide content, and — for an injected product — bacterial endotoxin and sterility failures, which are directly dangerous. This page does not recommend, rank or link any vendor. Purity, identity and chirality are unverifiable in this market, and for a compound whose mechanism is to kill cells, that is not a footnote.

Safety

There is no human safety data for FOXO4-DRI whatsoever, and the mechanism is the deliberate induction of apoptosis by manipulating p53. Selectivity is the entire safety question, and it has never been tested in a human — while one published study found this exact intervention worsened pulmonary hypertension.

Safety at a Glance

❔ Toxicity unknown

• Clearing senescent cells worsened pulmonary hypertension. An independent 2023 finding of harm from the exact intervention this compound performs — not a theoretical worry.
• No human data of any kind. No trial, no pharmacokinetics, no toxicology, no genotoxicity and no carcinogenicity study — on a mechanism that manipulates the p53 tumor suppressor.
• Some senescent cells are doing useful work. Senescence limits fibrosis in wound healing and is one of the body’s principal tumor-suppressive brakes.
• Not assessed in pregnancy or breastfeeding. See the box below.
• Designed to resist clearance, with no off-switch. Human residence time is unmeasured, and there is no antidote or reversal agent.
• Self-experiment anecdotes are not data. No control, no blinding, no verified product, no biomarker — and in the earliest account, a direct commercial interest.

Full Safety & Interactions Detail

This is the most important section here, and the honest version of it is short on data and long on reasons for caution.

Overall posture. There is no human safety data for FOXO4-DRI whatsoever. There is no clinical trial, no human pharmacokinetics, no formal toxicology study, no genotoxicity study and no carcinogenicity study. There is no pharmacovigilance system and no regulator collecting adverse events, so even serious harms in the self-experimenting population would be invisible. Everything below is drawn from animal work and from mechanism, and is labeled as such. Absence of reported harm here is absence of anyone looking.

Selectivity is the entire safety question. FOXO4-DRI does not “clear damage” — it induces apoptosis in cells it identifies as senescent. Whether that is safe depends completely on whether the identification is accurate, and there are two reasons to doubt that it is cleanly so:

• Senescence markers are not perfectly specific. Senescence is a heterogeneous, context-dependent state with no single defining marker. A peptide acting on the FOXO4–p53 axis acts on a pathway that is active well beyond canonical senescent cells, and off-target killing of non-senescent cells is a plausible and unmonitored risk.
• Some senescent cells are doing useful work. Senescence is a physiological program, not simply a defect. It limits fibrosis during wound healing, contributes to tissue remodeling, and — critically — is one of the body’s principal tumor-suppressive mechanisms: cells that would otherwise become cancerous are pushed into senescence instead. Indiscriminately removing them removes that brake.

The 2023 Circulation result is the concrete demonstration that this is not a theoretical worry: clearing senescent cells by three independent methods, FOXO4-DRI among them, worsened pulmonary hypertension ^{16Reference 16Born E et al. · 2023AnimalEliminating senescent cells can promote pulmonary hypertension development and progression — animal (mouse) / human tissueView study →}. That is a real, published, independent finding of harm from the exact intervention this compound performs.

p53 interference cuts both ways oncologically. The mechanism is deliberate manipulation of p53 — the most important tumor suppressor in human biology — by disrupting a protein interaction that controls its localization. The optimistic reading is that releasing p53 in damaged cells is protective. The pessimistic reading is that chronically perturbing p53 signaling with a long-residence synthetic peptide is precisely the kind of intervention that ought to be assessed for carcinogenicity before anyone injects it. No such assessment exists. Note also that the commercial development of this mechanism is being pursued in p53-mutant cancers — which is to say, the people who understand the pathway best treat it as an oncology-grade intervention requiring oncology-grade safety work, not a wellness compound.

Long tissue residence, no off-switch. The D-retro-inverso design is chosen to resist proteolysis. That is the point of the molecule, and it also means the body’s normal route for clearing a foreign peptide is largely unavailable. Human residence time is unmeasured. If an adverse effect emerged, there is no antidote, no reversal agent, and no data on how long exposure would persist.

Immunogenicity. A 46-residue synthetic construct with a highly cationic cell-penetrating tail is a plausible immunogen, and cationic cell-penetrating peptides carry known concerns about membrane disruption at higher concentrations. Neither has been characterized for this compound in humans.

From the animal work. The founding study described the peptide as well tolerated under its tested intravenous regimen in mice ^{1Reference 1Baar MP et al. · 2017In vitroTargeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging — animal (mouse) / in vitroView study →}. That is a statement about mice, at 5 mg/kg, three times, in a short experiment. It is not a human safety claim, and it says nothing about repeated or chronic exposure.

Injection-specific risks. Because it is injected after reconstitution from gray-market powder, the ordinary parenteral hazards apply and are among the most likely near-term harms: injection-site reactions, infection and abscess, endotoxin exposure, and dosing errors from imprecize reconstitution — compounded here by the stereochemistry uncertainty described above.

Interactions. Not assessed. No controlled human interaction data exist. Co-use with chemotherapy and radiotherapy is an active research theme (it protected against doxorubicin toxicity in mice ^{1Reference 1Baar MP et al. · 2017In vitroTargeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging — animal (mouse) / in vitroView study →} and was studied alongside radiotherapy ^{5Reference 5Meng J et al. · 2021In vitroTargeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis — animal (mouse) / in vitroView study →}), but that is a reason to be more careful, not less: these are interactions with cytotoxic therapy, studied only in animals.

Self-experimentation — a sociological fact, not evidence. FOXO4-DRI has been self-administered by members of the biohacking and longevity community since shortly after the 2017 paper. The longevity site Fight Aging! documented an early single-person self-experiment in 2017 by an individual who also sold the peptide, using injected doses in the tens of milligrams, and published a follow-up guide to running such self-experiments in 2018; the site’s own commentary criticized the effort for measuring no useful endpoints, concluding only that it did not appear immediately catastrophic. Comment-thread reports of feeling “a decade younger” circulate alongside it. None of this is evidence of anything. There is no control, no blinding, no verified product identity, no biomarker, no follow-up, and a direct commercial interest in the original account. It is recorded here because a reader will encounter these stories and should know exactly what they are: uncontrolled anecdotes from people injecting an unverified compound, which is also the only “human data” that exists.

Who should avoid it. Realistically, everyone outside a supervised clinical trial. Specifically: anyone with an active or prior malignancy or a family cancer history (p53 pathway interference, unassessed carcinogenicity); anyone with pulmonary hypertension or pulmonary vascular disease (the Circulation finding); anyone healing from injury or surgery (senescence has a role in wound repair); pregnant or breastfeeding individuals; and anyone unable to verify product identity, chirality and sterility — which, given the market, is essentially everyone.

Dose-limiting effect. None established. No dose-finding study has ever been run in a human.

Scope disclosure (what has and hasn’t been assessed):

• Human data? None — no trial, no PK, no toxicology. Cell and mouse data only.
• Interactions assessed? No — chemotherapy and radiotherapy combinations studied only in animals and cells.
• Pregnancy/lactation assessed? No — no data; avoid.
• Genotoxicity / carcinogenicity assessed? No — neither study exists, on a mechanism that directly manipulates the p53 tumor-suppressor pathway.
• Long-term safety established? No. There is no human safety data at any timescale, and no system that would detect harm if it occurred.

Never imply safety from silence. Where FOXO4-DRI hasn’t been studied in humans — which is everywhere — the honest statement is “not assessed,” not “safe.”

Pregnancy & Lactation

? Not established in pregnancy? Not established in lactation

Not assessed / not established. There are no human pregnancy or lactation data and no reproductive-toxicity studies. A pro-apoptotic, p53-activating peptide with long tissue residence is mechanistically the class of agent one would most want excluded from pregnancy, but there is no study or label statement to cite. Treat as unknown and avoid.

Dosage

There is no established human dose for FOXO4-DRI, and none is recommended here. It has no approved indication, no human pharmacokinetic study, and no dose-finding trial of any kind, so there is no basis on which a human dose could be derived. This page makes no dosing recommendation.

For reference only, the animal regimen from the founding study was 3 × 5 mg/kg intravenously on alternating days in mice ^{1Reference 1Baar MP et al. · 2017In vitroTargeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging — animal (mouse) / in vitroView study →}. That figure should not be scaled to a person. Allometric conversion from mouse to human is unreliable at the best of times; it is meaningless here, because the peptide’s human clearance and tissue residence are entirely unmeasured, and the D-retro-inverso design specifically alters the elimination behavior that such scaling assumes.

Figures circulating in community protocols — commonly cited in the range of tens of milligrams per subcutaneous injection over a short “course” — are un-validated, derive from no trial, and originated in part with people selling the compound. They also use a route (subcutaneous) for which no efficacy data exist at all, since the published work is intravenous. Treat them as sociological facts about how the peptide is sold and discussed, not as a protocol. Until a human PK profile and a dose-finding study exist, any human dose is unestablished.

References

1. Baar MP, Brandt RMC, Putavet DA, et al. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging — animal (mouse) / in vitro. Cell. https://pubmed.ncbi.nlm.nih.gov/28340339/
2. Krimpenfort P, Berns A. (2017). Rejuvenation by therapeutic elimination of senescent cells — commentary. Cell. https://pubmed.ncbi.nlm.nih.gov/28340347/
3. Han X, Yuan T, Zhang J, et al. (2022). FOXO4 peptide targets myofibroblast, ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway — animal (mouse). J Cell Mol Med. (Correction published J Cell Mol Med 2024;28:e18502.) https://pubmed.ncbi.nlm.nih.gov/35510614/
4. Liu Y, Hou Q, Wang R, et al. (2023). FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice — animal (mouse). Naunyn Schmiedebergs Arch Pharmacol. https://pubmed.ncbi.nlm.nih.gov/37074394/
5. Meng J, et al. (2021). Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis — animal (mouse) / in vitro. JCI Insight. https://pubmed.ncbi.nlm.nih.gov/34877934/
6. Le HH, Cinaroglu SS, Manalo EC, et al. (2021). Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells — in vitro / computational. EBioMedicine. https://pubmed.ncbi.nlm.nih.gov/34689087/
7. Kang D, Lim Y, Ahn D, et al. (2025). Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis — in vitro. J Med Chem. https://pubmed.ncbi.nlm.nih.gov/40739602/
8. Zhang C, et al. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice — animal (mouse) / in vitro. Aging (Albany NY). https://pubmed.ncbi.nlm.nih.gov/31959736/
9. Li Y, Zhang C, Cheng H, et al. (2024). FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells — animal (mouse). Exp Gerontol. https://pubmed.ncbi.nlm.nih.gov/39025385/
10. Kong YX, Li ZS, Liu YB, et al. (2025). FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation — in vitro (human cells/tissue). Commun Biol. https://pubmed.ncbi.nlm.nih.gov/39994346/
11. Huang Y, He Y, Makarcyzk MJ, Lin H. (2021). Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes — in vitro (human cells). Front Bioeng Biotechnol. https://pubmed.ncbi.nlm.nih.gov/33996787/
12. Hu Z, Li F, Hu C, et al. (2025). FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway — in vitro. Front Bioeng Biotechnol. https://pubmed.ncbi.nlm.nih.gov/41625068/
13. Alameen AAM, Al-Kuraishy HM, Fawzy MN, Batiha GE. (2026). Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline — narrative review. Naunyn Schmiedebergs Arch Pharmacol. https://pubmed.ncbi.nlm.nih.gov/42024235/
14. Bourgeois B, Spreitzer E, Platero-Rochart D, et al. (2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — in vitro (structural NMR; co-authored by the originating investigator, part-funded by Cleara Biotech). Nat Commun. https://pubmed.ncbi.nlm.nih.gov/40593617/
15. Kohoutova K, Srb P, Obsilova V, et al. (2025). Structural plasticity of the FOXO-DBD:p53-TAD interaction — in vitro (structural NMR; FOXO4/p53 proteins only — the FOXO4-DRI peptide was not tested in this study). Nat Commun. https://pubmed.ncbi.nlm.nih.gov/40425537/
16. Born E, Lipskaia L, Breau M, et al. (2023). Eliminating senescent cells can promote pulmonary hypertension development and progression — animal (mouse) / human tissue. Circulation. https://pubmed.ncbi.nlm.nih.gov/36515093/
17. Han Y, et al. (2023). DNA nanoparticles targeting FOXO4 selectively eliminate cigarette smoke-induced senescent lung fibroblasts — in vitro (alternative delivery, not the DRI peptide). Nanoscale Adv. https://pubmed.ncbi.nlm.nih.gov/37881696/

View all 17 references▾